Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.07
-0.0700-6.14%
Post-market: 1.090.0200+1.87%19:36 EDT
Volume:134.26K
Turnover:145.69K
Market Cap:6.00M
PE:-0.30
High:1.18
Open:1.15
Low:1.03
Close:1.14
52wk High:5.40
52wk Low:1.03
Shares:5.61M
Float Shares:5.28M
Volume Ratio:1.32
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5719
EPS(LYR):-6.8265
ROE:-429.72%
ROA:-77.99%
PB:3.10
PE(LYR):-0.16

Loading ...

Imunon CEO Stacy Lindborg Joins Maxim Growth Summit Oncology Panel

Reuters
·
Yesterday

Imunon Converts USD 1.2 Million Debt into Newly Issued Preferred Shares

Reuters
·
Sep 29

Imunon - Enters Exchange Agreement with Streeterville Capital on Sept 28, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 29

Imunon - Exchanges $1.20 Mln A-1 Note for 120 Series B Preferred Shares at $10,000 Per Share - SEC Filing

THOMSON REUTERS
·
Sep 29

Imunon - Converts $1.20 Mln of Debt into Series B Preferred Stock

THOMSON REUTERS
·
Sep 29

Imunon Issues 120 Series B Preferred Shares in Unregistered Sale Under Note Exchange

Reuters
·
Sep 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Imunon (IMNN)

TIPRANKS
·
Sep 25

Imunon Highlights 14.7-Month Overall Survival Gain in Phase 2 IMNN-001 Ovarian Cancer Study as Phase 3 Trial Advances

Reuters
·
Sep 24

Imunon - Targets Ovation 3 Enrollment Completion in Q1 2029

THOMSON REUTERS
·
Sep 24

Imunon Makes the Frontline Case for Phase 3 Imnn-001 Study: 14.7-Month Os Signal, Historical Il-12 Safety Barriers Overcome, Enrolling Ahead of Plan

THOMSON REUTERS
·
Sep 24

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

GlobeNewswire
·
Sep 24

Imunon - Idmc Recommends Phase 2 Mrd Study Continue Without Modification After Safety Review

THOMSON REUTERS
·
Sep 22

Imunon IDMC Backs Continued Phase 2 IMNN-001 MRD Study After Safety Review

Reuters
·
Sep 22

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

GlobeNewswire
·
Sep 22

Imunon Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of Imnn-001

THOMSON REUTERS
·
Sep 10

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

GlobeNewswire
·
Sep 10

Imunon Sets R&D Day to Spotlight IMNN-001 Clinical Progress

Reuters
·
Sep 09

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

GlobeNewswire
·
Sep 09

Imunon General Counsel Susan Eylward Disposes of 2,525 Common Shares Worth $3,950.86

Reuters
·
Sep 02

Imunon to Host R&D Day Spotlighting Phase 3 Ovation 3 Trial for IMNN-001 in Ovarian Cancer

Reuters
·
Aug 26